2024-03-18 16:08:00
The first results of a small study presented by Danish pharmaceutical giant Novo Nordisk (NN) on its new experimental diet pill show a potential up to twice the effectiveness of alternatives Ozempic and Wegovy, The Local reports.
According to the company’s Phase 1 study, NN contributed to weight loss of 13 percent over three months.
Previous studies indicated that Ozempic and Wegovy resulted in weight loss of regarding six percent over the same period. However, experts note that more research is needed to evaluate the long-term effectiveness and safety of NN.
Unlike other semaglutide drugs such as Ozempic, Wegovy and Mounjaro, NN is taken in tablet form rather than as an injection. Like these drugs, NN mimics the hormone GLP-1, which reduces appetite, as well as amylin.
Results from the NN trial are expected to be available in the next year or so.
1710801261
#unique #formula #promises #amazing #results
